BioNTech SE (BNTX) Long-Term Investments (2018 - 2025)
BioNTech SE (BNTX) posted Long-Term Investments of $3.0 billion for Q4 2025, up 121.88% sequentially from $1.3 billion in Q4 2024, and up 121.88% YoY from $1.3 billion in Q4 2024.
BioNTech SE (BNTX) Long-Term Investments (2018 - 2025) Analysis & Trends
BioNTech SE has reported Long-Term Investments for 7 years, with the latest figure at $3.0 billion in Q4 2025.
- Quarterly Long-Term Investments rose 121.88% year-over-year to $3.0 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.0 billion (up 121.88% YoY) and the FY2025 annual result came in at $2.9 billion, up 115.35% from the prior year.
- Long-Term Investments grew to $3.0 billion in Q4 2025 per BNTX's latest filing, from $1.3 billion in the prior quarter.
- Over five years, Long-Term Investments peaked at $3.0 billion in Q4 2025 and troughed at $24.4 million in Q4 2021.
- A 5-year average of $981.8 million and a median of $686.8 million in 2023 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2022 and 2024: Long-Term Investments soared 637.76% in 2022, then gained 12.75% in 2024.
- Over 5 years, Long-Term Investments stood at $24.4 million in 2021, then jumped by 637.76% to $179.8 million in 2022, then jumped by 561.12% to $1.2 billion in 2023, then climbed by 12.75% to $1.3 billion in 2024, then surged by 121.88% to $3.0 billion in 2025.
- According to Business Quant data, Long-Term Investments over the past three periods registered $3.0 billion, $1.3 billion, and $1.2 billion for Q4 2025, Q4 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Roivant Sciences | 26.20 Bn | 26.20 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.97 Bn |
| Dec 31, 2024 | 1.13 Bn |
| Dec 31, 2023 | 1.19 Bn |
| Mar 31, 2023 | 185.04 Mn |
| Dec 31, 2022 | 179.77 Mn |
| Dec 31, 2021 | 24.37 Mn |
| Sep 30, 2019 | 60.32 Mn |
| Dec 31, 2018 | 55.49 Mn |